|
|
|
|
J&J unit wins $1.67 billion verdict vs Abbott Labs
Centocor Ortho Biotech Inc.Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a...
|
|
|
EULAR: Five-Year Data Show Continued Benefit for Infliximab in AS
COPENHAGEN, June 22 -- Patients with ankylosing spondylitis (AS) generally maintained the clinical responses to infliximab (Remicade) seen during a two-year randomized trial for three more years, it was reported here.Patients who...
|
|
|
Golimumab Shows Sustained Efficacy in Ankylosing Spondylitis Over 104 Weeks: Presented at EULAR
-- Patients with ankylosing spondylitis successfully treated with golimumab for 24 weeks have shown sustained treatment efficacy through week 104, researchers reported here at the 10th Annual Congress of the European League Against...
|
|
|
Reducing Work Disability in Ankylosing Spondylitis - Development of a Work Instability Scale for AS
(Click the title below to leave the MDLinx Network and go to the Journal's Website) BMC Musculoskeletal Disorders, 06/17/09 Print Save in My Library Free Full Text Gilworth G et al.- The AS-WIS is a self-administered scale which meets the...
|
|
|
Infliximab Shows Enduring Efficacy, Safety Over 8 Years in Patients With Ankylosing Spondylitis: Presented at
-- Infliximab appears to be safe and efficacious in patients with ankylosing spondylitis over an 8-year period, even after discontinuation and restart of treatment, researchers reported here on June 13 at the 10th Annual Congress of the...
|
|
|
Uveitis Is Less Frequent When Ankylosing Spondylitis Is Treated With Adalimumab
_ Uveitis Is Less Frequent When Ankylosing Spondylitis Is Treated With Adalimumab.
Abstracts in Hematology and Oncology:
Jun 15 2009 10:41PM
Matching: spondylitis ankylosing
|
Find similar documents
|
|
|
|
Uveitis Is Less Frequent When Ankylosing Spondylitis Is Treated With Adalimumab
_ Uveitis Is Less Frequent When Ankylosing Spondylitis Is Treated With Adalimumab.
|
|
|
Infliximab Response Varies in Ankylosing Spondylitis
_ Infliximab Response Varies in Ankylosing Spondylitis.
|
|
|
Infliximab Response Varies in Ankylosing Spondylitis
_ Infliximab Response Varies in Ankylosing Spondylitis.
Abstracts in Hematology and Oncology:
Jun 15 2009 5:37PM
Matching: spondylitis ankylosing
|
Find similar documents
|
|
|
|
Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R) at the European League Against Rheumatism
(PR Newswire Europe via COMTEX News Network) -- Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing ...
|
|
|
Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R) at the European League Against Rheumatism
MAIDENHEAD, England, June 12 /PRNewswire/ -- - Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing ...
|
|
|
Wyeth Presents New Analyses of Data From Three Studies of ENBREL(R) at th
MAIDENHEAD, England, June 12 /PRNewswire/ -- - Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing ...
|
|
|
Wyeth Presents New Analyses of Data From Three Studies of
Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing Spondylitis Indicated Improvement in...
|
|
|
Etanercept in the longterm treatment of patients with ankylosing spondylitis
An evaluation of the 2-yr efficacy and safety of etanercept in pts with AS A 96-wk open-label extension study, which followed a 12-wk double-blind placebo-controlled trial Pts were treated with etanercept 25 mg x2/wk In all, 81 pts were...
|
|
|
Fatigue in patients with ankylosing spondylitis: Relationships with disease-specific variables, depression, an
Frequency of fatigue and its multi-dimensional nature, and Its association with: Demographic variables Disease-specific variables, and Other variables, covering depression and sleep disturbance in patients with AS (n=62) Fatigue was assessed...
|
